Searched for
RARE DISEASE PORTFOLIO
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Moderna first-quarter revenue jumps on strong overseas COVID vaccine salesModerna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-tha...
- Soleno shares jump 33% as Neurocrine expands into metabolic diseases with $2.9 billion buyoutNeurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, mark...
- US Stocks: Apellis shares double on Biogen's $5.6 billion buyout planBiogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfoli...
- Biocon arm gets USFDA nod for generic Everolimus tabletsBiocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous s...
- Novartis to acquire Avidity Biosciences for about $12 billionNovartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...
- Bayer’s gene and cell therapy pipeline aims to transform Parkinson’s, oncology, rare diseases and moreBayer, through its subsidiary Viralgen, is advancing cell and gene therapies (CGT) to cure diseases like Parkinson's, oncology, cardiovascu...
- AstraZeneca's asthma drug fails 'smoker's lung' studyAstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the...
- AstraZeneca to invest Rs 176 cr to expand GITC in ChennaiAstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India...
- Sanofi buys US biopharma group Blueprint in $9.1 billion dealSanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt,...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- Zydus eyes M&A, licensing to build its US specialty businessZydus Lifesciences is exploring mergers, acquisitions, and licensing to bolster its specialty portfolio in the US, particularly for the pot...
- AstraZeneca to invest Rs 250 crore on expansion of its GCC in IndiaThe facility currently occupies 334,000 square feet of office space at Ramanujan IT City, with plans to add approximately 180,000 square fe...
- AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolioAstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...
- Zydus Lifesciences appoints Punit Patel as President & CEO, AmericasBefore joining Zydus, he was the President of Red Oak Sourcing, leading the company's "multibillion-dollar generic portfolio", overseeing a...
- Zydus' US subsidiary acquires speciality drug asset in USUnder the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and com...
- Sanofi bets on India with portfolio of drugs for diabetes, rare diseasesSanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...
- Lupin on buying spree; to acquire German company Temmler Pharma's product portfolioA day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...
Load More
